The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.
 
Ali Belkouz
No Relationships to Disclose
 
Judith de Vos-Geelen
No Relationships to Disclose
 
Ferry Eskens
Consulting or Advisory Role - Eisai; Ipsen; Merck Serono; Roche
Travel, Accommodations, Expenses - Pfizer
 
Ron A.A. Mathot
No Relationships to Disclose
 
Thomas van Gulik
No Relationships to Disclose
 
Martijn G.H. van Oijen
No Relationships to Disclose
 
Cornelis J. A. Punt
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Nordic Bioscience; Roche
 
Johanna Wilmink
No Relationships to Disclose
 
Heinz-Josef Kluempen
No Relationships to Disclose